Company profile: Affini-T Therapeutics
1.1 - Company Overview
Company description
- Provider of autologous TCR-T cell therapies targeting oncogenic driver mutations in solid tumors and off-the-shelf bispecific T cell engagers. Offers the TAILOR discovery platform leveraging machine learning and high-throughput screening, TUNE to enhance persistence and functionality via synthetic biology, and THRIVE for optimized manufacturing and gene editing. Conducts clinical trials.
Products and services
- TAILOR platform: Machine learning-driven discovery process that identifies potent TCRs against oncogenic driver peptides via high-throughput screening, enabling precise target selection for solid tumor applications
- Autologous TCR-T cell therapies: Custom-engineered T-cell products that target oncogenic driver mutations in solid tumors, harnessing TCR-mediated recognition to deliver precise antitumor activity
- Bispecific T Cell Engagers: Off-the-shelf biologics that activate T cells against cancer cells with specific oncogenic drivers for targeted anticancer activity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Affini-T Therapeutics
Aprea Therapeutics
HQ: Sweden
Website
- Description: Provider of oncology therapeutics focused on discovering and developing anticancer compounds that reactivate the tumor suppressor protein p53, including APR-246, a first-in-class small molecule drug candidate in clinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aprea Therapeutics company profile →
Sierra Oncology
HQ: United States
Website
- Description: Provider of targeted cancer therapeutics in clinical development, focused on rare forms of cancer. Leverages deep scientific expertise to identify compounds that target root causes of disease and advances therapies using an evidence-based approach.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sierra Oncology company profile →
ClearNote Health
HQ: United States
Website
- Description: Provider of cancer detection solutions, including the Avantect Pancreatic Cancer Test—a blood test that detects pancreatic cancer in its earliest stages by measuring the biomarker 5hmC; the Virtuoso Epigenomics Platform—a whole genome sequencing and 5hmC enrichment solution for revealing active disease biology for drug discovery and development; and targeted multi-cancer panels that track epigenomic signals via a single blood draw.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ClearNote Health company profile →
Boston Biomedical
HQ: United States
Website
- Description: Provider of biotechnology research and development focused on novel therapeutics to treat cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Boston Biomedical company profile →
Bolt Biotherapeutics
HQ: United States
Website
- Description: Provider of a biotechnology platform for cancer immunotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bolt Biotherapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Affini-T Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Affini-T Therapeutics
2.2 - Growth funds investing in similar companies to Affini-T Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Affini-T Therapeutics
4.2 - Public trading comparable groups for Affini-T Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →